Overview

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Status:
COMPLETED

Trial end date:
2025-04-28

Target enrollment:

Participant gender:

Summary

This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.

Phase:

PHASE1

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

PPD Development, LP